跳至主要内容
临床试验/NCT06480071
NCT06480071已完成不适用

The Role of Nasal Breathing for Perfomance in Elite Athletes

Sahlgrenska University Hospital, Sweden1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2022年1月13日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
12
试验地点
1
主要终点
VO2 max

研究概览

简要总结

This study investigates the contribution of nasal breathing to the performance during aerobic and anaerobic heavy exercise in 12 male elite cyclists. In a ramp test on a mechanically braked cycle ergometer (Monark LT2, Varberg, Sweden) VO2 max, heart rate, respiratory frequency, intranasal geometry and nasal airflow resitance as well as blood lactate and glucose was measured at each step of the ramp test and after a maximum exhaust test. Nasal breathing was randomized to three sepratae tests, normal open nose, decongested nose with oxymetazoline 0.5mg/ml, 2 sprays each nostril and with a nose clip. The study showed that in the test with the nose clip, mean blood lactate was significantly lower.

详细描述

Exercise experiments will be performed on12 elite male cyclists/triathletes, 20-40 years of age. The subjects should have a VO2max of ≥65 ml/min/kg. The subjects will perform pre-tests determining VO2max according to standard techniques. Subjects will be recruited through local contacts at clubs for cyclists and triathletes. Subjects should not have any medication, no nasal symptoms/disease and no asthma and be non-smokers. Subjects will be included after informed consent. All subjects answer a respiratory and training questionnaire. In total, all participants will undergo four visits to the exercise lab (CHP): the first visit for characterisation (pre-test) and the following three visits will be the exercise trials in a randomized order. All visits will take approximately 2 hours.

Experimental trials Diet and Activity Before Testing Participants will be instructed to refrain from alcohol and asked not to perform vigorous exercise on the day before each experimental trial, to record their diet on the first of these days, and to repeat this diet on days before subsequent trials.

Test day procedures Following an overnight fast, participants will be instructed to consume 500 ml plain water upon wakening. Upon arrival at the laboratory (CHP), height and nude body mass will be recorded, and a blood sample (hB) and a urine sample will be collected. A pre-trial urine specific gravity (USG) ≤1.025 (Atago, Tokyo, Japan) will be considered as a euhydrated state. Body composition will be assessed at the first experimental trial by dual-energy X-ray absorptiometry (iDXA; GE Medical Systems, Madison, WI, USA). Total fat and lean mass will be analyzed using enCore software (version 16.10).

Visual analogue scale for nasal symptoms will be recorded. The nose will be examined with anterior rhinometry and with a nasal endoscope. Spirometry will be performed. Intranasal geometry and nasal airway resistance will be measured immediately before during and after the exercise test.

Following the anthropometric measurements, an incremental maximal laboratory test will be performed on a mechanically braked cycle ergometer (Monark LT2, Varberg, Sweden) adapted with a racing saddle, drop handlebars, and clip-in pedals. Initial workload will be set at 110 W and increased by 35 W every 6 min, with 2-min recovery intervals/data collection points between workloads. With assistance of a metronome, pedal rate will be kept constant at 75 rpm through the entire test. Testing will be continued until the participant no longer can maintain the required pedal rate. Heart rate (HR) will be recorded every 5 s throughout the test (Polar Electro OY, model S10i, Finland). Blood samples (Figure) will be obtained to determine blood lactate concentration ([Lac]) and glucose immediately after each completed workload. [Lac] values attained during the last workload will be considered to be maximal. Maximal power output (Wmax) will be determined as the highest workload the participant can maintain for a complete 6-min period. Environmental conditions during the experimental trials will be approximately 20°C and 40-50% relative humidity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • male subjects
  • age 18-40
  • elite cyclists or Triathlon athletes
  • minimum VO2max of ≥65 ml/min/kg on pretest.

排除标准

  • <18>40 years of age
  • non-elite cyclists or Triathlon athletes
  • less than VO2max of ≥65 ml/min/kg on pretest

研究组 & 干预措施

Nasal decongestion during exercise

Experimental

Nasal decongestion with oxymetazomin nasal spray 0.05% 2 sprays each nostril 10 minutes before the exercise test

干预措施: Oxymetazoline, 0.05% Nasal Spray (Drug)

结局指标

主要结局

VO2 max

时间窗: 7 minutes per cycle

maximum oxygen upptake during exrecise

blood lactate

时间窗: 7 minutes per cycle

lactic acid, a cmponent produced during anaerobic heavy exercise

Effect

时间窗: 7 minutes per cycle

Watt effect generated during exercise

次要结局

  • HR(7 minutes per cycle)
  • nasal air flow resistance(7 minutes per cycle)

研究者

发起方
Sahlgrenska University Hospital, Sweden
申办方类型
Other
责任方
Principal Investigator
主要研究者

Johan Hellgren

Professor

Sahlgrenska University Hospital, Sweden

研究点 (1)

Loading locations...

相似试验